Dr. Vivian Vega reviews several interesting Infectious Diseases cases she has managed over the last several years, and includes relavant ID-related pearls about diagnosis and management. From an infectious diseases conference recorded in September 2020.
Dr. Anthony Cannella, Associate Director of Epidemiology at the James A Haley Veterans Hospital, presents a series of clinical cases from his years in infectious diseases practice. The cases are presented in a visual, interactive format. From a virtual session originally recorded on August 19, 2020.
Dr. Mercurio reviews antimicrobial susceptibility testing methods and explains how this data reported with culture results can be best used to make informed antibiotic treatment decisions. Dr. Mercurio begins by discussing the difference between MIC and MBC, and the misconceptions about MIC values for different antibiotic agents. Next, she reviews recent changes in the susceptibility breakpoints for several bacterial organisms, including Enterococcus spp., Staphylococcus aureus, Enterobacteriaceae, and Pseudomonas. Lastly, she reviews the resistance issues with the “SPACE/SPICE” bacteria as well as inducible clindamycin resistance, and closes with comments on heteroresistance issues in bacterial populations.
Dr. John Greene, Chief of Infectious Diseases at Moffitt Cancer Center, reviews disorders involving the gastrointestinal tract. Syndromes discussed include Cholera, traveller’s diarrhea, Typhoid fever, Salmonellosis, Campylobacter, pathogenic E coli, Echinococcosis, aeromonas, and Vibrio. Dr. Greene presents the topics in a fast paced, photo quiz format.
In a follow-up to his presentation recorded in May 2020, Dr. Oehler presents ten current coronavirus myths or assertions circulating online today and comments on their legitimacy or inaccuracy. Topics covered include the importance of wearing masks, the differences in types of masks for the public, whether recent protests led to increased cases of COVID-19 in those communities, the phenomenon of “COVID parties,” the adequacy of U.S. coronavirus testing, the long term effects of COVID-19, and whether a Coronavirus vaccine will be available by early 2021.
Dr. Toney reviews the epidemiology and management of Varicella Zoster infections. He first discusses the prevalence and clinical presentation of this herpesvirus family infection. He points out the importance of recognizing the prodrome in patients before the complete outbreak occurs. He goes on to discuss the clinical complications of VZV disease, including ophthalmologic, multi-dermatomal, and disseminated infections. He next discusses the treatment options available to manage Zoster infections. The subject of available Zoster vaccines is then discussed, with a focus on the newer Recombinant Zoster Vaccine (RZV). Lastly, Dr. Toney presents a couple of photo case-studies.
Dr. Baluch provides an overview of how to structure an infection control program for a hospital. She reviews the different types of infection control precautions (standard, contact, droplet, special, airborne). She also addresses specific situations such as with measles and with stem cell transplant patients and other immunocompromised individuals.
Dr. Shewayish shows how public health is an essential component of economic prosperity. This is at no time more a poignant argument than in the midst of the current pandemic, where it is clear that the key to economic recovery is to vanquish the coronavirus outbreak. As we have seen in the Spring and early Summer of 2020, infectious diseases can affect a large swath of the business sector, from agriculture, to manufacturing, transportation, hospitality/travel, and many others. Some industries may have a business model that is incompatible with an infection outbreak. Others may ride the wave of increased demand that occurs as a result of the disease’s impact on society. A disease outbreak may also cause individuals to withdraw from the economy due to fear, job loss, or reduced services. Investing in public health is an endeavor that pays countless dividends. As the pandemic shows, societies around the world need to do more to invest in the health of their populations and in preparing for the next outbreak that may impact us.
Dr. Teo presents a thorough review of the currently available treatment options for COVID-19 disease. He begins by summarizing the evidence for available antiviral treatment options. Next, he discusses the available data for several pharmacologic support therapies currently under investigation. Lastly, he presents the NIH and/or IDSA recommendations regarding those therapies. Therapies discussed include hydroxychloroquine, remdesivir, HIV protease inhibitor, Favipiravir, Tocilizumab, interferons, and others. Dr. Teo also looks at convalescent plasma and its promising role in certain patients with severe COVID-19.